MARKET

VBLT

VBLT

Vascular
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.615
-0.045
-2.71%
Closed 16:00 05/24 EDT
OPEN
1.680
PREV CLOSE
1.660
HIGH
1.680
LOW
1.511
VOLUME
139.52K
TURNOVER
134.57K
52 WEEK HIGH
3.040
52 WEEK LOW
1.100
MARKET CAP
111.98M
P/E (TTM)
-3.4590
1D
5D
1M
3M
1Y
5Y
Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue Estimates
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -8.33% and 42.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/17 12:15
Recap: Vascular Biogenics Q1 Earnings
  Vascular Biogenics (NASDAQ:VBLT) reported its Q1 earnings results on Tuesday, May 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/17 11:48
BRIEF-VBL Therapeutics Reports First Quarter 2022 Financial Results And Provides Corporate Update
reuters.com · 05/17 11:13
Vascular Biogenics Q1 EPS $(0.13) Misses $(0.11) Estimate, Sales $113.00K Miss $200.00K Estimate
Vascular Biogenics (NASDAQ:VBLT) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 8.33 percent decrease over losses of $(0.12) per share
Benzinga · 05/17 11:08
VBL Therapeutics GAAP EPS of -$0.13 misses by $0.01, revenue of $0.11M misses by $0.09M
VBL Therapeutics press release (NASDAQ:VBLT): Q1 GAAP EPS of -$0.13 misses by $0.01. Revenue of $0.11M (-38.9% Y/Y) misses by $0.09M. At March 31, 2022, VBL had cash, cash equivalents,
Seekingalpha · 05/17 11:02
VBL Therapeutics Q1 2022 Earnings Preview
VBL Therapeutics (NASDAQ:VBLT) is scheduled to announce Q1 earnings results on Tuesday, May 17th, before market open. The consensus EPS Estimate is -$0.12 (flat Y/Y) and the consensus Revenue Estimate
Seekingalpha · 05/16 16:42
Notable earnings before Tuesday's open
AER, ALLT, BPTH, OTCPK:ENGIY, OTCQB:GAXY, HD, HUYA, OTCQX:IMBBY, JD, JMIA, KMDA, MDWD, OBSV, ONON, PTN, REE, RSKD, SE, VBLT, VOD, WMT, XNET For Seeking Alpha's full earnings season calendar, click here.
Seekingalpha · 05/16 16:23
Earnings Preview For Vascular Biogenics
Vascular Biogenics (NASDAQ:VBLT) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that Vascular Biogenics will report an earnings per share (EPS) of $-...
Benzinga · 05/16 14:06
More
No Data
Learn about the latest financial forecast of VBLT. Analyze the recent business situations of Vascular through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
80.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VBLT stock price target is 5.30 with a high estimate of 7.00 and a low estimate of 4.000.
High7.00
Average5.30
Low4.000
Current 1.615
EPS
Actual
Estimate
-0.10-0.08-0.05-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 41
Institutional Holdings: 8.23M
% Owned: 11.87%
Shares Outstanding: 69.34M
TypeInstitutionsShares
Increased
3
21.98K
New
6
3.27M
Decreased
6
194.37K
Sold Out
8
321.89K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.05%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Non-Executive Chairman/Independent Director
Bennett Shapiro
Chief Executive Officer/Director
Dror Harats
Non-Executive Vice Chairman/Independent Director
Marc Kozin
Chief Financial Officer
Sam Backenroth
Vice President - Operations
Eyal Breitbart
Vice President
Erez Feige
Vice President
Tami Rachmilewitz
Vice President
Naamit Sher
General Counsel
Ayelet Horn
Secretary
Amos Ron
Director
Alison Finger
Director
Michael Rice
Non-Executive Independent Director
Ruth Alon
Non-Executive Independent Director
Shmuel Ben Zvi
Non-Executive Independent Director
Ron Cohen
Non-Executive Independent Director
David Hastings
No Data
No Data
About VBLT
Vascular Biogenics Ltd. is Israel- based late-stage clinical biopharmaceutical company, focused on the discovery, development and commercialization of treatments for cancer. VBL’s clinical pipeline is based on two distinct platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. The Company has developed two programs based on these platforms an oncology program and an anti-inflammatory program. The Company’s lead oncology product VB-111, is a targeted anti-cancer gene-therapy agent that is positioned to potentially treat a wide range of solid tumors. VBL has also developed platform of investigational orally-available small molecules, designated Lecinoxoids, for the treatment of chronic immune-related indications.

Webull offers kinds of Vascular Biogenics Ltd stock information, including NASDAQ:VBLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VBLT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VBLT stock methods without spending real money on the virtual paper trading platform.